Skip to main content
English

Suche

  1. Home
  2. Suche

Webseiten-Inhalte

Researcher of the MedUni Vienna ...Jing Ning, M.D. Department of Biomedical Imaging and Image-guided Therapy (Clinical Division of Nuclear Medicine)Position: PHD Student ORCID: 0000-0001-5059-2401T +43 1 40400 55450 jing.ning@meduniwien.ac.at Keywords Animal models; Digital Histopathology; Genomics; Molecular Imaging; Nuclear Medicine; Oncology Research group(s) Christian Doppler Laboratory for Applied MetabolomicsHead: Lukas KennerResearch Area: We investigate ways to better characterize tumors using non-invasive imaging techniques. This is important because tumours are constantly changing through mutations. In this way, an individual therapy should be possible and its success should be continuously monitored.Members: Marko Grahovac David Haberl Lukas Kenner Kilian Kluge Marzieh Nejabat Jing Ning Computational Nuclear MedicineMembers: Barbara Katharina Geist David Haberl Marzieh Nejabat... https://www.meduniwien.ac.at/web/en/forschung/researcher-profiles/researcher-profiles/detail/?res=jing_ning&cHash=c6947e8501df689433c27578d68fe497
Researcher of the MedUni Vienna ...Jing Ning, M.D. Department of Biomedical Imaging and Image-guided Therapy (Clinical Division of Nuclear Medicine)Position: PHD Student ORCID: 0000-0001-5059-2401T +43 1 40400 55450 jing.ning@meduniwien.ac.at Keywords Animal models; Digital Histopathology; Genomics; Molecular Imaging; Nuclear Medicine; Oncology Research group(s) Christian Doppler Laboratory for Applied MetabolomicsHead: Lukas KennerResearch Area: We investigate ways to better characterize tumors using non-invasive imaging techniques. This is important because tumours are constantly changing through mutations. In this way, an individual therapy should be possible and its success should be continuously monitored.Members: Marko Grahovac David Haberl Lukas Kenner Kilian Kluge Marzieh Nejabat Jing Ning Computational Nuclear MedicineMembers: Barbara Katharina Geist David Haberl Marzieh Nejabat... https://www.meduniwien.ac.at/web/en/forschung/researcher-profiles/researcher-profiles/detail/index.php?id=688&res=jing_ning
Researcher of the MedUni Vienna ...Jing Ning, M.D. Department of Biomedical Imaging and Image-guided Therapy (Clinical Division of Nuclear Medicine)Position: PHD Student ORCID: 0000-0001-5059-2401T +43 1 40400 55450 jing.ning@meduniwien.ac.at Keywords Animal models; Digital Histopathology; Genomics; Molecular Imaging; Nuclear Medicine; Oncology Research group(s) Christian Doppler Laboratory for Applied MetabolomicsHead: Lukas KennerResearch Area: We investigate ways to better characterize tumors using non-invasive imaging techniques. This is important because tumours are constantly changing through mutations. In this way, an individual therapy should be possible and its success should be continuously monitored.Members: Marko Grahovac David Haberl Lukas Kenner Kilian Kluge Marzieh Nejabat Jing Ning Computational Nuclear MedicineMembers: Barbara Katharina Geist David Haberl Marzieh Nejabat... https://www.meduniwien.ac.at/web/forschung/researcher-profiles/researcher-profiles/detail/?res=jing_ning&cHash=8080089fde79efc7533426fb28d9540f
Researcher of the MedUni Vienna ...Jing Ning, M.D. Department of Biomedical Imaging and Image-guided Therapy (Clinical Division of Nuclear Medicine)Position: PHD Student ORCID: 0000-0001-5059-2401T +43 1 40400 55450 jing.ning@meduniwien.ac.at Keywords Animal models; Digital Histopathology; Genomics; Molecular Imaging; Nuclear Medicine; Oncology Research group(s) Christian Doppler Laboratory for Applied MetabolomicsHead: Lukas KennerResearch Area: We investigate ways to better characterize tumors using non-invasive imaging techniques. This is important because tumours are constantly changing through mutations. In this way, an individual therapy should be possible and its success should be continuously monitored.Members: Marko Grahovac David Haberl Lukas Kenner Kilian Kluge Marzieh Nejabat Jing Ning Computational Nuclear MedicineMembers: Barbara Katharina Geist David Haberl Marzieh Nejabat... https://www.meduniwien.ac.at/web/forschung/researcher-profiles/researcher-profiles/detail/index.php?id=688&res=jing_ning
Researcher of the MedUni Vienna ...Jing Ning, M.D. Department of Biomedical Imaging and Image-guided Therapy (Clinical Division of Nuclear Medicine)Position: PHD Student ORCID: 0000-0001-5059-2401T +43 1 40400 55450 jing.ning@meduniwien.ac.at Keywords Animal models; Digital Histopathology; Genomics; Molecular Imaging; Nuclear Medicine; Oncology Research group(s) Christian Doppler Laboratory for Applied MetabolomicsHead: Lukas KennerResearch Area: We investigate ways to better characterize tumors using non-invasive imaging techniques. This is important because tumours are constantly changing through mutations. In this way, an individual therapy should be possible and its success should be continuously monitored.Members: Marko Grahovac David Haberl Lukas Kenner Kilian Kluge Marzieh Nejabat Jing Ning Computational Nuclear MedicineMembers: Barbara Katharina Geist David Haberl Marzieh Nejabat... https://www.meduniwien.ac.at/web/forschung/researcher-profiles/researcher-profiles/index.php?id=688&res=jing_ning
Researcher of the MedUni Vienna ...Jing Ning, M.D. Department of Biomedical Imaging and Image-guided Therapy (Clinical Division of Nuclear Medicine)Position: PHD Student ORCID: 0000-0001-5059-2401T +43 1 40400 55450 jing.ning@meduniwien.ac.at Keywords Animal models; Digital Histopathology; Genomics; Molecular Imaging; Nuclear Medicine; Oncology Research group(s) Christian Doppler Laboratory for Applied MetabolomicsHead: Lukas KennerResearch Area: We investigate ways to better characterize tumors using non-invasive imaging techniques. This is important because tumours are constantly changing through mutations. In this way, an individual therapy should be possible and its success should be continuously monitored.Members: Marko Grahovac David Haberl Lukas Kenner Kilian Kluge Marzieh Nejabat Jing Ning Computational Nuclear MedicineMembers: Barbara Katharina Geist David Haberl Marzieh Nejabat... https://www.meduniwien.ac.at/web/index.php?id=688&res=jing_ning
Researcher of the MedUni Vienna ...Jing Ning, M.D. Department of Biomedical Imaging and Image-guided Therapy (Clinical Division of Nuclear Medicine)Position: PHD Student ORCID: 0000-0001-5059-2401T +43 1 40400 55450 jing.ning@meduniwien.ac.at Keywords Animal models; Digital Histopathology; Genomics; Molecular Imaging; Nuclear Medicine; Oncology Research group(s) Christian Doppler Laboratory for Applied MetabolomicsHead: Lukas KennerResearch Area: We investigate ways to better characterize tumors using non-invasive imaging techniques. This is important because tumours are constantly changing through mutations. In this way, an individual therapy should be possible and its success should be continuously monitored.Members: Marko Grahovac David Haberl Lukas Kenner Kilian Kluge Marzieh Nejabat Jing Ning Computational Nuclear MedicineMembers: Barbara Katharina Geist David Haberl Marzieh Nejabat... https://www.meduniwien.ac.at/web/1/forschung/researcher-profiles/researcher-profiles/index.php?id=688&res=jing_ning
Vielversprechender Prognose- und Therapie-Ansatz bei Mastozytose ...Uni Vienna und Lukas Kenner (Klinisches Institut für Pathologie) konnte außerdem gezeigt werden, dass CCL-2 für das Wachstum von Mastzelltumoren wesentlich ist. Für die Behandlung von Brust- und Prostatakarzinomen, wo ebenfalls erhöhte CCL-2-Spiegel vorliegen, werden bereits Antikörper getestet, die... https://www.meduniwien.ac.at/web/ueber-uns/news/detailseite/2016/news-im-dezember-2016/vielversprechender-prognose-und-therapie-ansatz-bei-mastozytose/?tx_news_pi1%5BoverwriteDemand%5D%5Bcategories%5D=2&cHash=78894d435bc13448a8ce076c8365d691
Vielversprechender Prognose- und Therapie-Ansatz bei Mastozytose ...Uni Vienna und Lukas Kenner (Klinisches Institut für Pathologie) konnte außerdem gezeigt werden, dass CCL-2 für das Wachstum von Mastzelltumoren wesentlich ist. Für die Behandlung von Brust- und Prostatakarzinomen, wo ebenfalls erhöhte CCL-2-Spiegel vorliegen, werden bereits Antikörper getestet, die... https://www.meduniwien.ac.at/web/ueber-uns/news/detailseite/2016/news-im-dezember-2016/vielversprechender-prognose-und-therapie-ansatz-bei-mastozytose/?cHash=9a02fce1cd9a57b1a19d8a55b7d2ef19&tx_news_pi1%5BoverwriteDemand%5D%5Bcategories%5D=11
Vielversprechender Prognose- und Therapie-Ansatz bei Mastozytose ...Uni Vienna und Lukas Kenner (Klinisches Institut für Pathologie) konnte außerdem gezeigt werden, dass CCL-2 für das Wachstum von Mastzelltumoren wesentlich ist. Für die Behandlung von Brust- und Prostatakarzinomen, wo ebenfalls erhöhte CCL-2-Spiegel vorliegen, werden bereits Antikörper getestet, die... https://www.meduniwien.ac.at/web/ueber-uns/news/detailseite/2016/news-im-dezember-2016/vielversprechender-prognose-und-therapie-ansatz-bei-mastozytose/?tx_news_pi1%5BoverwriteDemand%5D%5Bcategories%5D=11&cHash=9a02fce1cd9a57b1a19d8a55b7d2ef19